PubMed HealthSearch

PubMed · 6448746

A monoclonal antibody blocking human T cell function.

Abstract

The possible functional role of T cell surface antigens defined by monoclonal antibodies was investigated. Five monoclonal anti-T cell reagents as well as an anti-Ia and anti-beta 2-microglobulin antibody were examined for their effect on T cell function. It was shown that an antibody termed anti-T3, reactive with all peripheral T cells, blocked T cell proliferative responses to soluble and cell surface antigens. This inhibition was seen when T lymphocytes were treated with as few as 10(4) anti-T3 molecules per cell. Although anti-T3 could block the generation of cytotoxic T cells in mixed lymphocyte culture, once generated, anti-T3 had no effect on cytotoxicity. In addition, anti-T3 abrogated the ability of T cells to provide help to B cells in a pokeweed mitogen-driven immunoglobulin system. More importantly, these functional effects were not seen with the other monoclonal antibodies. Both the appearance of this antigen in intrathymic ontogeny and its critical role in T cell function suggests that the T3 molecule is related to an important antigen recognition receptor or cell-cell interactions molecule.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E L Reinherz, R E Hussey, S F Schlossman. 1980. A monoclonal antibody blocking human T cell function.. https://doi.org/10.1002/eji.1830101006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies